Spatial protein heterogeneity analysis in frozen tissues to evaluate tumor heterogeneity.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
07
2021
accepted:
19
10
2021
entrez:
19
11
2021
pubmed:
20
11
2021
medline:
24
12
2021
Statut:
epublish
Résumé
A new workflow for protein-based tumor heterogeneity probing in tissues is here presented. Tumor heterogeneity is believed to be key for therapy failure and differences in prognosis in cancer patients. Comprehending tumor heterogeneity, especially at the protein level, is critical for tracking tumor evolution, and showing the presence of different phenotypical variants and their location with respect to tissue architecture. Although a variety of techniques is available for quantifying protein expression, the heterogeneity observed in the tissue is rarely addressed. The proposed method is validated in breast cancer fresh-frozen tissues derived from five patients. Protein expression is quantified on the tissue regions of interest (ROI) with a resolution of up to 100 μm in diameter. High heterogeneity values across the analyzed patients in proteins such as cytokeratin 7, β-actin and epidermal growth factor receptor (EGFR) using a Shannon entropy analysis are observed. Additionally, ROIs are clustered according to their expression levels, showing their location in the tissue section, and highlighting that similar phenotypical variants are not always located in neighboring regions. Interestingly, a patient with a phenotype related to increased aggressiveness of the tumor presents a unique protein expression pattern. In summary, a workflow for the localized extraction and protein analysis of regions of interest from frozen tissues, enabling the evaluation of tumor heterogeneity at the protein level is presented.
Identifiants
pubmed: 34797831
doi: 10.1371/journal.pone.0259332
pii: PONE-D-21-20606
pmc: PMC8604290
doi:
Substances chimiques
Biomarkers, Tumor
0
Neoplasm Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0259332Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Mod Pathol. 2018 Mar;31(3):406-417
pubmed: 29148540
Nat Commun. 2020 Jan 7;11(1):8
pubmed: 31911630
Biotechniques. 2013 May;54(5):257-64
pubmed: 23662896
Cancers (Basel). 2012 Dec 21;5(1):1-11
pubmed: 24216695
J Pathol. 1997 Sep;183(1):116-23
pubmed: 9370957
Cancer Res. 2018 Oct 15;78(20):6001-6010
pubmed: 30154156
Sci Rep. 2016 Feb 09;6:20277
pubmed: 26856369
Proteomics. 2016 Jun;16(11-12):1622-32
pubmed: 26929135
Analyst. 2014 Feb 7;139(3):528-42
pubmed: 24326290
Nature. 2020 Feb;578(7796):615-620
pubmed: 31959985
Nat Commun. 2016 Jan 04;7:10259
pubmed: 26725330
Langmuir. 2011 May 3;27(9):5686-93
pubmed: 21476506
Biotechniques. 2004 Jan;36(1):84-6, 88, 90-1
pubmed: 14740490
Virchows Arch. 2016 Jan;468(1):19-29
pubmed: 26306713
Anal Chem. 2020 Dec 15;92(24):15719-15725
pubmed: 33259186
Histopathology. 2012 Oct;61(4):660-6
pubmed: 22748158
Lab Invest. 2012 Sep;92(9):1342-57
pubmed: 22801299
Rapid Commun Mass Spectrom. 2013 Jun 30;27(12):1329-34
pubmed: 23681810
J Vis Exp. 2011 Oct 25;(56):e3334
pubmed: 22064683
Clin Adv Hematol Oncol. 2016 Mar;14(3):186-93
pubmed: 27058032
Int J Mol Sci. 2018 May 09;19(5):
pubmed: 29747452
Anal Chem. 2017 Mar 7;89(5):2948-2955
pubmed: 28193007
Carcinogenesis. 2017 Sep 1;38(9):900-909
pubmed: 28911002
PLoS One. 2012;7(7):e40285
pubmed: 22792263
Nat Methods. 2014 Apr;11(4):417-22
pubmed: 24584193
Nucleic Acids Res. 2020 Feb 20;48(3):e17
pubmed: 31853536
Nat Commun. 2014 Mar 05;5:3421
pubmed: 24594667
Angew Chem Int Ed Engl. 2019 Oct 21;58(43):15259-15262
pubmed: 31529566
BMC Cancer. 2015 Mar 18;15:138
pubmed: 25880075
J Pathol. 2004 Jun;203(2):661-71
pubmed: 15141381
Mol Cell. 2015 Nov 19;60(4):537-46
pubmed: 26590713
Nat Biotechnol. 2019 Sep;37(9):1080-1090
pubmed: 31427819
Arch Pathol Lab Med. 2008 Dec;132(12):1929-35
pubmed: 19061293
Virchows Arch. 2012 Sep;461(3):313-22
pubmed: 22851038
Oncogene. 2020 Mar;39(12):2478-2492
pubmed: 31988452
Methods. 2014 Nov;70(1):12-9
pubmed: 24561827
Am J Cancer Res. 2017 Aug 01;7(8):1617-1636
pubmed: 28861319
Breast Cancer (Auckl). 2018 Aug 01;12:1178223418788074
pubmed: 30083055
Am J Pathol. 2002 Dec;161(6):1991-6
pubmed: 12466114
Mol Cell Proteomics. 2014 Dec;13(12):3497-506
pubmed: 25225357
J Natl Cancer Inst. 2018 Jul 1;110(7):726-733
pubmed: 29361175
Nat Commun. 2020 Jan 27;11(1):532
pubmed: 31988290
Transl Oncol. 2014 Oct;7(5):613-9
pubmed: 25048628
Breast Cancer Res. 2003;5(6):R217-22
pubmed: 14580257
Mol Clin Oncol. 2016 Apr;4(4):648-654
pubmed: 27073684
Nat Med. 2001 Apr;7(4):493-6
pubmed: 11283679
Mol Cell Proteomics. 2018 Sep;17(9):1864-1874
pubmed: 29941660
Breast Cancer Res. 2007;9(1):R4
pubmed: 17217540
Cell. 2019 May 16;177(5):1330-1345.e18
pubmed: 30982598
Ann Surg Oncol. 2019 Jul;26(7):2191-2199
pubmed: 30963401
Sci Rep. 2016 Jul 14;6:29579
pubmed: 27411740
Anal Chem. 2013 Mar 5;85(5):2717-23
pubmed: 23402265
Expert Rev Proteomics. 2009 Apr;6(2):145-57
pubmed: 19385942
Nat Med. 2002 Nov;8(11):1323-7
pubmed: 12389040
J Pathol Inform. 2016 Nov 29;7:47
pubmed: 27994939
Oncotarget. 2018 May 1;9(33):23264-23273
pubmed: 29796187
Nat Rev Genet. 2010 Oct;11(10):733-9
pubmed: 20838408
Anal Chem. 2017 Jun 6;89(11):5683-5687
pubmed: 28492310
Nat Rev Clin Oncol. 2015 Jul;12(7):381-94
pubmed: 25895611
Nat Biomed Eng. 2019 Sep;3(9):684-694
pubmed: 31285580
Anal Biochem. 1979 Oct 1;98(2):445-51
pubmed: 91332
Nat Biomed Eng. 2019 Jun;3(6):478-490
pubmed: 30962588
J Proteomics. 2011 Sep 6;74(10):1884-94
pubmed: 21596165